Skip to main
SNTI

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences is a clinical-stage biotechnology company with a positive outlook due to their gene circuit platform and promising pipeline. The company's current clinical trial for SENTI-202, a blood cancer treatment, has shown impressive results with the use of the "Donor X" phenotype, which is found in approximately 50% of adult donors and does not present any operational constraints. However, there are risks associated with financing and manufacturing that could impact future progress and share dilution for investors. Overall, the potential for success in the gene therapy space and the company's current progress make Senti Biosciences a promising investment opportunity.

Bears say

Senti Biosciences is a clinical stage biotechnology company focused on developing cell and gene therapies for incurable diseases through its proprietary gene circuit platform. However, while its lead candidate, SENTI-202, has shown promising results in a heavily pretreated AML population, there are still uncertainties around the regulatory approval and commercial potential of such therapies. Additionally, the company's need for additional financing and potential competition from other players in the cell therapy space pose risks to future profitability.

SNTI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Holdings Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 3 analysts, SNTI has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Holdings Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.